KEYNOTE: Market Growth and Drivers in Chinese Animal Health

1. 致力健康事业 共创美好生活
Market Growth and Drivers in China
Animal Health
Dr. Yongsheng Wang
Vice President of Jinyu Bio-Technology Co. Ltd.
General Manager of Jinyu Baoling Bio-pharma Co. Ltd

2. Forward-Looking Statement
• These statements are based upon the current beliefs and expectations of Jinyu’s
management and are subject to significant risks and uncertainties. If underlying
assumptions prove inaccurate or risks or uncertainties materialize, actual results
may differ materially from those set forth in the forward-looking statements.
• Risks and uncertainties include but are not limited to, general industry conditions
and competition; general economic factors, including interest rate and currency
exchange rate fluctuations; the impact of industry regulation and animal health
legislation in China; trends of animal health product cost; technological
advances, new products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory approval; Jinyu’s
ability to accurately predict future market conditions; manufacturing difficulties or
delays; dependence on the effectiveness of Jinyu’s patents and other protections
for innovative products; and the exposure to litigation, including patent litigation,
and/or regulatory actions.
• Jinyu undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise. Additional
factors that could cause results to differ materially from those described in the
forward-looking statements can be found in Jinyu’s 2015 Annual Report and the
company’s other filings with the Shanghai Stock Exchange (SSE) available at the
SSE’s Internet site (www.sse.com.cn).

3. Personal Experiences
• Vice President of Jinyu Bio-Technology Co. Ltd.; General
Manager of Jinyu Baoling Bio-pharma Co. Ltd since May 2014
• Vice President of MSD (Merck) China and General Manager of
MSD Animal Health China during Jan, 2013 to April 2014.
• Worked in Pfizer Animal Health (Zoetis) in different roles as
Director of Public Affairs in APAC, General Manager, National
Sales Manager, Regulatory Affairs Manager & National Technical
Service Manager in China during 1997-2012.
• Got Ph.D degree from China Agricultural University, major in
Bio-technology of animal reproduction, and also had master and
bachelor degree in veterinary medicine.

4. Outline
• Animal Health Market in China
• Growth & Key Drivers in China Animal Health
• Briefing of Jinyu Bio-Technology Co. Ltd.

5. Animal Husbandry Industry
Pork, 65%
Chicken,
25%
Beef/Mutt
on, 10%
Meat Consumption
• Animal husbandry is one of major agro-industry
• High output value：290 Billion RMB
• 28.3% of total agro-industry output
• Swine production value account 18% of Agro-industry
Output of main animal products (10.000 MT）

6. Livestock Industry
• Swine
• Output 735.1 million in 2014, 2.7%G
• Inventory of sow: 42.89 million, -14.7%G
• Market 13.74 pigs per sow per year
• Cattle
• Inventory: 103.85 million, - 0.16%G
• Inner Mongolian：62.50 million, -0.14%G
• Dairy
• Inventory: 14.20 million, -0.14%G
• Inner Mongolian：335 million，23.6% of
nation total
• Sheep/Goat
• Inventory: 285.04million, 0.95%G
• Inner Mongoliany：51.44 million, 18% of
total
• Sheep Inventory: 143.67 million，2.9%G
• Inner Mongolian：34.84 million，24.3% of
total
• Goat inventory: 141.36 million, - 0.97%G
• Inner Mongolian：16.60 million, 11.7% of
total
Inventory of livestock ( 10.000)
Cattle Sheep/goat Pig

7. Poultry Industry
• Broiler
• Output: 855 MM,
-8%G
• White：-8%G
• Yellow：-11%G
 Layer
◦ Inventory: 144.5 MM，-1%G
◦ Grandparent breeding: 512,4
thousand; 6 big farms
◦ Parent breeding：17.8 MM
◦ No. 1 egg production in the
world since 1985
Million

8. Animal Health Industry
• 2014 total market is 40.7
billion RMB, Bios 10.4
billion RMB
• CAGR is 10.84% from 2007
to 2014
• There are 1809 companies
for animal health, 82 for
vaccine
• Swine & poultry vaccine
dominated vaccine market
• Swine: 4.88 billion RMB, account
47%
• Poultry: 3.67 billion RMB,
account 35.4%

9. Animal Health Industry
• Mandatory Vaccine: 5.56 billion RMB
• FMD, AI
• PRRS & CSF will exit the list from (2017
• Brucellosis & Peste des petits ruminants virus (PPRV) will be
added
• Swine vaccine dominated
MandatoryCommon Pig
Poultry
Ruminant

10. Animal Health Industry
• Innovation
• 2014 investment in R&D is 2.73 billion, 6.7% of total
revenue

11. 35%
52%
70%
28%
40%
55%
68%
73%
80%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
2010 2015E 2020E
• Output increase of livestock & poultry
• MOA issue 2016-2020 development plan for swine and ruminant
industry
• Productive efficiency improve
• market 19 pigs per sow per year by 2020
• Ratio of commercial farms increase
Pig Layer Broiler
Growth & Key Drivers

12. Growth & Key Drivers
• Animal health market will growth more than 10%
annually
• Need high quality animal health products, especially
vaccines
• Vaccines for private market will replace vaccines for
tender market, and drive the growth
1.0%
1.1%
1.2%
1.3%
1.4%
1.5%
1.6%
1.7%
1.8%
0
5
10
15
20
25
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Cost of Swine Vaccines per Pig
Small farm Commercial far Commercial Farm G% Small farm G%

13. Growth & Key Drivers
• Companion animal
market quick growth
• Number of CA growth
• Expenses for CA increment
• More specific care
required (arthritis,
obesity, diabetes)
150 million dog Annual Expense
Market size Growth %
100 million

14. Growth & Key Drivers
• R&D investment increase
• Innovative products & technologies
will replace classic ones
• Merger and acquisition will
speed up concentration
ration
• BI+Merial
• Jinhe (Pharmgate LLC) acquired
Prota Tek International Inc
• Ruipu Bio-technology acquired
Huana Bio-technology

15. Jinyu Briefing
• Found in 1993
• Headquartered: Hohhot, Inner Mongolia
• Listed at ShangHai Stock Exchange in 1998 （stock code
600201）
• Engaged in animal health industry (AH) since 1995,
focused on bio-pharmaceutical by divesting real estate
business in early of 2013
• Market Value: $2.85 billion by Oct. 15, 2016
• Employees: 990
• Two manufacturing sites
• Jinyu Baoling
• Yangzhou Youbang

16. Jinyu Briefing
Core
Advantages
R&D Advantages
• National Engineering Lab of Animal
Vaccine
• National Engineering Lab of Animal
Vaccine
• National High-Level Biosafety Lab
• First launch trivalent inactivated
vaccine of FMD (O, Asia I & A）for
cattle and genetic engineering vaccine
of FMD (O) for swine
First Mover Advantages
• First break down the technical barrier of using bioreactor for
animal vaccine production in China
• Leading vaccine company for cattle, sheep/goat and pig
• First one to promote FMD vaccine directly to farmers
Quality Advantages
• High content of FMD antigen
• Content of non-antigen protein and endotoxin in FMD
vaccine decrease 90% compare to classic ones
• Using 1/5 serum in producing FMD vaccine compare
with rotating bottle culture
• no antibiotic residue
Technology/Process
Advantafes
• Cell suspension culture
• concentration and purification
• Remove of non-antigen protein more
than 98%
• 146S quantitative detection for FMD
antigen
• PCR Mycoplasma Testing: quick,
high
specificity and sensitivity
•:Identify subtypes of FMD virus by
specific FMD primers design

17. Jinyu Briefing
• Marketing & Sales：
• 4 specific sales team with 150 person (direct sales, swine,
ruminant, tender)
• Excellent marketing network (channel) covering 31 provinces
• Dedicated technical service team with 29 staffs
• Collaboration
• Since 2012，start strategic and technologic exchanges with
famous pharmaceutic/vaccine companies from France,
Switzerland, Germany, USA etc.
• Sign collaborative agreement with Ceva for brucellosis vaccine
in 2013
• Project with Ethiopia government
• Project with Gates Foundation

18. Jinyu Briefing
• Market position
• Leading animal vaccine company with market share 12% in
China in 2015
• No. 1 FMD vaccine company in China
• Direct sales: >60% market share
• Government procurement tendering: 23% market share
Revenue (10,000 RMB） Growth %

19. Jinyu Briefing
• Biological Science & Technology Industrial Park
• Four functional areas: Veterinary bio-pharmaceutics, Human bio-
pharmaceutics, Sino-foreign joint venture of biochemical
pharmaceutics, R&D supporting and other comprehensive facilities
• Cover total area of more than 500,000 M2
• 1st phase investment: 2.5 billion RMB
• Construction period: about 3 years

20. Jinyu Briefing
• Dedicate to a healthier and better lifeVision
• Protecting animal safety, ensuring human
healthMission
• Responsibility, Innovation, ValueValue
• Being a globalized leading company in bio-
pharmaceutical industry by introducing new
technology, expanding portfolio and marketing
Strategic
Objective

21. 致力健康事业 共创美好生活
Thank you!
Looking forward to cooperation in near future
Cell Phone：+86 15847663222
Email：wangyongsheng@jinyubaoling.com.cn